ABLA
AMPH icon

Alan B. Lancz & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Alan B. Lancz & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,400
Closed -$201K – 124
2024
Q4 		$201K Hold
5,400
– – 0.2% 121
2024
Q3 		$262K Hold
5,400
– – 0.24% 106
2024
Q2 		$216K Buy
+5,400
New +$224K 0.21% 116

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alan B. Lancz & Associates's AMPH Position: Q1 2025 in Review

Alan B. Lancz & Associates sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2025, closing a stake of 5,400 shares — an estimated $201K sold.

Alan B. Lancz & Associates first reported a position in AMPH in Q2 2024 and held it in 3 quarters. The position peaked at $262K in Q3 2024. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • Alan B. Lancz & Associates reported no remaining Amphastar Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alan B. Lancz & Associates sold 5,400 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $201K.
  • Alan B. Lancz & Associates first reported a position in Amphastar Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Alan B. Lancz & Associates's Amphastar Pharmaceuticals position peaked at $262K in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2025, filed 30 Apr 2025.